EYPT
EyePoint, Inc.
$13.66
+1.86%
2026-05-08
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Key Fundamentals
Forward P/E
-4.81
EPS (TTM)
$-3.51
ROE
-102.7%
Revenue Growth (YoY)
161.7%
Profit Margin
0.0%
Debt/Equity
46.82
Price/Book
3.61
Beta
1.77
Market Cap
$1.12B
Avg Volume (10D)
873K
Recent Breakout Signals
No recent breakout signals detected for EYPT.
Recent Price Range (60 Days)
60D High
$18.87
60D Low
$11.82
Avg Volume
1.2M
Latest Close
$13.66
Get breakout alerts for EYPT
Sign up for Breakout Scanner to receive daily notifications when EYPT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
EyePoint, Inc. (EYPT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors EYPT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. EYPT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.